L ike in Western Europe, the fi rst case of HIV was observed in Greenland in the mid-1980s (1), but the epidemic in this isolated polar country has evolved differently compared with other industrialized countries (2) . In a previous study we showed that most patients were infected through heterosexual contact and were middle-aged at the time of diagnosis. Many patients belonged to a socially marginalized group characterized by low income, unemployment, and heavy drinking. Even though highly active antiretroviral therapy (HAART) is tax-supported and free, we found an overall mortality rate of 11% per year for patients given HAART during 1997 HAART during -2003 . In a molecular epidemiologic study, we showed that HIV was introduced at least 9 times into Greenland, and that one of these introductions has given rise to a circulating epidemic that has included 76% of all infected persons (3) . Recently, we found 28% prevalence of transmitted drug resistance, corresponding well with the impression of low drug adherence and high risk behavior (T.V. Madsen et al., unpub. data). Contributing to the disappointing results could be the vast geography with often long distances to healthcare facilities, the short supply of specialized physicians, and the composition of the HIV-infected population. In 2002 the overall responsibility for treating HIV patients was transferred to the Department of Internal Medicine at Dronning Ingrids Hospital, Greenland's main hospital, located in the capital, Nuuk. The chief physician at that department takes care of HIV patients in Nuuk and supervises treatment of HIV patients in other areas. With access to data from all HIVinfected persons in Greenland and Denmark, we aimed to compare the Implementation and effectiveness of HAART during 1997-2007 in 3 areas: Nuuk; Greenland's remote districts (all towns and settlements except Nuuk); and the Western European country of Denmark, the former colonial power with which Greenland still has tight economical, social, and constitutional bonds.
The Study
The population-based Danish HIV Cohort Study (DHCS) collects clinical and paraclinical data on all HIVinfected persons under care in Denmark and Greenland since 1995 (2,4), including antiretroviral treatment, HIV RNA (viral load), and date of death or emigration. Patients from DHCS were followed from fi rst visit to an HIV clinic until date of death, emigration, or last visit to the clinic. To estimate viral loads and CD4 cell counts between measurements, we carried forward the last observed value. HAART was defi ned as combination antiretroviral treatment with at least 3 drugs, including at least 1 protease inhibitor (PI), or 1 non-nucleoside reverse transcriptase inhibitor (NNRTI), or abacavir. On January 1 for each year of the study we estimated the proportion of patients receiving HAART, each antiretroviral drug class, and selected antiretroviral drugs. National guidelines in both countries have recommended HAART initiation at a CD4 cell count <300 cells/μL, a threshold that has not changed since 1997. Among patients who had never received HAART, we estimated the proportion with a CD4 cell count <300 cells/μL, and among patients who had begun a HAART regimen at least 90 days previously, we estimated the proportion with a viral load <400 copies/mL. Annual mortality rates (MR) in the HIV population were estimated by person-years analysis; Poisson regression was used to test for trends over time.
Conclusions
Among 124 HIV patients in Greenland, 98 (79%) were infected through heterosexual contact, 78 (63%) were male, 111 (90%) were Inuit, and 98 (79%) were infected in Greenland. The median age at diagnosis was 50 years (interquartile range [IQR] 40-57 years), and the median CD4 cell count at diagnosis was 350 cells/μL (IQR 220-530 cells/μL). Among 4,702 HIV patients in Denmark, 2,114 (45%) were infected through homosexual contact, 1,745 (37%) through heterosexual contact, and 537 (11%) through intravenous drug use; 3,542 (75%) were male; 3,723 (79%) were Caucasian, and 650 (14%) black African. Half, 2,370, were infected in Denmark, 725 (15%) in Africa, and 1,046 (22%) unknown; the median age at diagnosis was 34 years (IQR 28-42). The median CD4 cell count at diagnosis was 284 cells/μL (IQR 108-490 cells/μL). In Greenland only 3% had begun HAART on January 1, 1997, as opposed to 28% in Denmark (Figure 1 Treatment of HIV patients in Greenland began at a later stage of disease and has been implemented at a slower pace with lower therapeutic effectiveness than in Denmark, despite comparable economic means, general education of healthcare personnel, and common therapeutic guidelines. From other studies we know that patient support and education improve adherence (6) and that guideline-recommended therapy is more likely to be chosen if the physician is specialized in HIV and has >20 HIV patients in care (7), regardless of whether this physician is a generalist or infectious disease specialist. We observed marked improve- team in Nuuk and were most pronounced in that city when compared with the remote districts. Even though this temporal association does not prove causation, the improvements are likely to be partly attributable to the increased focus on HIV in the capital. The MR among HIV patients in Nuuk in recent years was higher than that in Denmark, but part of this difference may be attributable to a high background mortality rate among HIV-uninfected persons in Greenland (2, 8) and an older HIV-infected population. As previously reported, sexually active persons in Greenland undergo frequent HIV testing (2) , and CD4 cell counts were high at diagnosis, ruling out late testing as a contributor to the high MR. In conclusion, healthcare systems in the sparsely populated and isolated polar areas may be less fi t to take on state-of-the-art care and treatment for HIV or other diseases previously unknown in the area, and an extra effort from the such providers may be needed to maximize control of the disease.
